Sensyne Health PLC - clinical artificial intelligence technology company with headquarters in Oxford - Signs research collaboration agreement with US pharmaceutical firm Bristol Myers Squibb Co.
Partnership will focus on applying Sensyne's proprietary machine learnings to conduct research into disease progression and stratification for patients with various diseases within the broader group of myeloproliferative neoplasms.
MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells - red blood cells, white blood cells and platelets.
No financial terms were disclosed.
Current stock price: 102.68 pence
Year-to-date change: up 49%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.